Prognostic Factors for Patients with Early-stage Uterine Serous Carcinoma Without Adjuvant Therapy

Overview

Journal J Gynecol Oncol

Specialties Gynecology & Obstetrics
Oncology

Date 2018 Mar 14

PMID 29533019

Citations 9

Authors

Keisei Tate

Hiroshi Yoshida

Mitsuya Ishikawa

Takashi Uehara

Shun Ichi Ikeda

Nobuyoshi Hiraoka

Tomoyasu Kato

Affiliations

Soon will be listed here.

Abstract

Objective: Uterine serous carcinoma (USC) is an aggressive type 2 endometrial cancer. Data on prognostic factors for patients with early-stage USC without adjuvant therapy are limited. This study aims to assess the baseline recurrence risk of early-stage USC patients without adjuvant treatment and to identify prognostic factors and patients who need adjuvant therapy.

Methods: Sixty-eight patients with International Federation of Gynecology and Obstetrics (FIGO) stage I-II USC between 1997 and 2016 were included. All the cases did not undergo adjuvant treatment as institutional practice. Clinicopathological features, recurrence patterns, and survival outcomes were analyzed to determine prognostic factors.

Results: FIGO stages IA, IB, and II were observed in 42, 7, and 19 cases, respectively. Median follow-up time was 60 months. Five-year disease-free survival (DFS) and overall survival (OS) rates for all cases were 73.9% and 78.0%, respectively. On multivariate analysis, cervical stromal involvement and positive pelvic cytology were significant predictors of DFS and OS, and ≥1/2 myometrial invasion was also a significant predictor of OS. Of 68 patients, 38 patients had no cervical stromal invasion or positive pelvic cytology and showed 88.8% 5-year DFS and 93.6% 5-year OS.

Conclusion: Cervical stromal invasion and positive pelvic cytology are prognostic factors for stage I-II USC. Patients with stage IA or IB USC showing negative pelvic cytology may have an extremely favorable prognosis and need not receive any adjuvant therapies.

Citing Articles

Development of Antibody-Drug Conjugates for Malignancies of the Uterine Corpus: A Review.

Yamanaka T, Nishikawa T, Yoshida H Cells. 2025; 14(5).

PMID: 40072062 PMC: 11898814. DOI: 10.3390/cells14050333.

Range of Resection in Endometrial Cancer-Clinical Issues of Made-to-Measure Surgery.

Horala A, Szubert S, Nowak-Markwitz E Cancers (Basel). 2024; 16(10).

PMID: 38791927 PMC: 11120042. DOI: 10.3390/cancers16101848.

Prognostic Value of Peritoneal Cytology in Stage I Serous and Clear Cell Carcinoma of the Endometrium.

Yang J, Yang J, Cao D, Wu M, Xiang Y J Clin Med. 2023; 12(4).

PMID: 36836143 PMC: 9959011. DOI: 10.3390/jcm12041609.

The Impact of Adjuvant Management Strategies on Outcomes in Women With Early Stage Uterine Serous Carcinoma.

Cook A, Khalil R, Burmeister C, Dimitrova I, Elshaikh M Cureus. 2021; 13(2):e13505.

PMID: 33786214 PMC: 7992918. DOI: 10.7759/cureus.13505.

Combined Adjuvant Chemotherapy and Radiation Therapy Improves Disease-Free Survival for Uterine Serous Cancer.

Arden J, Marvin K, Ye H, Juratli L, Nandalur S, Al-Wahab Z Adv Radiat Oncol. 2020; 5(6):1232-1239.

PMID: 33305084 PMC: 7718545. DOI: 10.1016/j.adro.2020.08.013.

References

Han K, Park N, Kim H, Chung H, Kim J, Song Y . Peritoneal cytology: a risk factor of recurrence for non-endometrioid endometrial cancer. Gynecol Oncol. 2014; 134(2):293-6. DOI: 10.1016/j.ygyno.2014.05.010. View

Hachisuga T, Fukuda K, Iwasaka T, Hirakawa T, Kawarabayashi T, Tsuneyoshi M . Endometrioid adenocarcinomas of the uterine corpus in women younger than 50 years of age can be divided into two distinct clinical and pathologic entities based on anatomic location. Cancer. 2001; 92(10):2578-84. DOI: 10.1002/1097-0142(20011115)92:10<2578::aid-cncr1610>3.0.co;2-v. View

Hamilton C, Cheung M, Osann K, Chen L, Teng N, Longacre T . Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006; 94(5):642-6. PMC: 2361201. DOI: 10.1038/sj.bjc.6603012. View

Fader A, Drake R, OMalley D, Gibbons H, Huh W, Havrilesky L . Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer. 2009; 115(10):2119-27. DOI: 10.1002/cncr.24247. View

Westin S, Lacour R, Urbauer D, Luthra R, Bodurka D, Lu K . Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol. 2008; 26(36):5965-71. PMC: 2645115. DOI: 10.1200/JCO.2008.18.6296. View

Creasman W, Kohler M, Odicino F, Maisonneuve P, Boyle P . Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol. 2004; 95(3):593-6. DOI: 10.1016/j.ygyno.2004.08.019. View

Dietrich 3rd C, Modesitt S, Depriest P, Ueland F, Wilder J, Reedy M . The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2005; 99(3):557-63. DOI: 10.1016/j.ygyno.2005.07.104. View

van der Putten L, Hoskins P, Tinker A, Lim P, Aquino-Parsons C, Kwon J . Population-based treatment and outcomes of Stage I uterine serous carcinoma. Gynecol Oncol. 2013; 132(1):61-4. DOI: 10.1016/j.ygyno.2013.11.002. View

Bokhman J . Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15(1):10-7. DOI: 10.1016/0090-8258(83)90111-7. View

10.

Huh W, Powell M, Leath 3rd C, Straughn Jr J, Cohn D, Gold M . Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol. 2003; 91(3):470-5. DOI: 10.1016/j.ygyno.2003.08.027. View

11.

Boruta 2nd D, Gehrig P, Fader A, Olawaiye A . Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009; 115(1):142-153. DOI: 10.1016/j.ygyno.2009.06.011. View

12.

Burke W, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye A . Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol. 2014; 134(2):393-402. DOI: 10.1016/j.ygyno.2014.06.003. View

13.

Santin A, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J . Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002; 8(5):1271-9. View

14.

Fader A, Java J, Tenney M, Ricci S, Gunderson C, Temkin S . Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol. 2016; 143(3):460-465. PMC: 5116702. DOI: 10.1016/j.ygyno.2016.10.016. View

15.

Kandoth C, Schultz N, Cherniack A, Akbani R, Liu Y, Shen H . Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497(7447):67-73. PMC: 3704730. DOI: 10.1038/nature12113. View

16.

Garg G, Gao F, Wright J, Hagemann A, Mutch D, Powell M . Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer. Gynecol Oncol. 2012; 128(1):77-82. PMC: 3992288. DOI: 10.1016/j.ygyno.2012.09.026. View

17.

Creutzberg C, van Putten W, Koper P, Lybeert M, Jobsen J, Warlam-Rodenhuis C . Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000; 355(9213):1404-11. DOI: 10.1016/s0140-6736(00)02139-5. View

18.

Kelly M, OMalley D, Hui P, McAlpine J, Yu H, Rutherford T . Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol. 2005; 98(3):353-9. DOI: 10.1016/j.ygyno.2005.06.012. View

19.

Carmen M, Birrer M, Schorge J . Uterine papillary serous cancer: a review of the literature. Gynecol Oncol. 2012; 127(3):651-61. DOI: 10.1016/j.ygyno.2012.09.012. View